Diagnosis of Fatal Human Case of St. Louis Encephalitis Virus Infection by Metagenomic Sequencing, California, 2016

Charles Y. Chiu, Lark L. Coffey, Jamie Murkey, Kelly Symmes, Hannah A. Sample, Michael R. Wilson, Samia N. Naccache, Shaun Arevalo, Sneha Somasekar, Scot Federman, Doug Stryke, Paul Vespa, Gary Schiller, Sharon Messenger, Romney Humphries, Steve Miller, Jeffrey D. Klausner

We used unbiased metagenomic next-generation sequencing to diagnose a fatal case of meningoencephalitis caused by St. Louis encephalitis virus in a patient from California in September 2016. This case is associated with the recent 2015–2016 reemergence of this virus in the southwestern United States.

St. Louis encephalitis virus (SLEV), in the Flaviviridae family, is an infectious RNA virus transmitted by Culex spp. mosquitoes (1,2). Clinical manifestations range from mild febrile illness to fatal neurologic disease. According to recent reports (3,4), SLEV reemerged in the summer of 2015 in California and Arizona, USA, after a documented 11-year absence of activity in California.

In June 2016, we launched a multi-institutional clinical study titled Precision Diagnosis of Acute Infectious Diseases (PDAID). This 1-year study aimed to enroll 300 patients to evaluate the clinical utility of a metagenomic next-generation sequencing (mNGS) assay for diagnosing infectious causes of meningitis and encephalitis from patient cerebrospinal fluid (CSF) samples (5,6). The mNGS assay uses an unbiased sequencing approach to comprehensively identify pathogens (viruses, bacteria, fungi, and parasites) in clinical samples (7). We report a fatal human case of SLEV infection diagnosed by mNGS in a PDAID study patient from California.

The Case
The case-patient was a 68-year-old man with a history of coronary artery disease, hypertension, and mantle cell lymphoma treated with 4 cycles of chemotherapy and granulocyte colony stimulating factor. He sought medical care at the end of August 2016 having had 2 days of fever (up to 39.4°C), chills, lethargy, and confusion. He had fallen twice because of dizziness and reported shortness of breath, cough, and new-onset urinary incontinence.

The patient was a retired oil-field worker living with his wife in Bakersfield, Kern County, California. He owned 1 dog and had frequent contact with his 10 grandchildren. His travel history was notable for a trip to “the mountains” in late April 2016 (Payson, Arizona, elevation 1,500 m).

The patient was admitted to the hospital in early September 2016. An initial workup, including magnetic resonance imaging of the brain, was unrevealing. Empirical therapy with vancomycin, meropenem, and levofloxacin was started after lung imaging revealed inflammatory pneumonitis. On hospitalization day 3, the patient became acutely hypoxic with worsening altered mental status (AMS), and he was intubated and transferred to the intensive care unit. A lumbar puncture revealed CSF pleocytosis (18 leukocytes/mm³; 35% monocytes, 33% lymphocytes, and 32% neutrophils); glucose and protein were within reference ranges. Empiric antibiotic therapy was continued, and acyclovir and antifungal therapy were added to his regimen. Repeat lumbar puncture performed on hospital day 9 showed persistent pleocytosis. All microbiologic test results for CSF, blood, and bronchoalveolar lavage were negative (Table 1), as was a workup for noninfectious causes (online Technical Appendix, https://wwwnc.cdc.gov/EID/article/23/10/16-1986-Techapp1.pdf).

After enrolling the patient in the PDAID study, we analyzed CSF from hospitalization day 9 by mNGS testing at University of California, San Francisco (online Technical Appendix) (8). RNA and DNA sequencing libraries from CSF yielded 8,056,471 and 9,083,963 sequence reads, respectively. In the RNA library, 236,615 (2.9%) of the reads were identified as SLEV by using the SURPI+ (sequence-based ultra-rapid pathogen identification) computational pipeline (7), with recovery of 99.4%...
### Table 1.
Microbiologic testing results for a patient with fatal mosquito-borne St. Louis encephalitis virus infection diagnosed by metagenomic sequencing, California, 2016

<table>
<thead>
<tr>
<th>Test</th>
<th>Hospitalization day sample collected</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum studies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bacterial cultures</td>
<td>0, 2, 4, 7</td>
<td>Negative</td>
</tr>
<tr>
<td>Fungal cultures</td>
<td>0, 2, 4, 7</td>
<td>Negative</td>
</tr>
<tr>
<td>Mycobacterial culture</td>
<td>10</td>
<td>Negative</td>
</tr>
<tr>
<td>Aspergillus antigen EIA</td>
<td>5</td>
<td>Negative</td>
</tr>
<tr>
<td>Adenovirus PCR</td>
<td>19</td>
<td>Negative</td>
</tr>
<tr>
<td>CMV DNA quantitative PCR</td>
<td>4, 12</td>
<td>Negative</td>
</tr>
<tr>
<td>EBV DNA quantitative PCR</td>
<td>10</td>
<td>Negative</td>
</tr>
<tr>
<td>Enterovirus RNA</td>
<td>19</td>
<td>Negative</td>
</tr>
<tr>
<td>HSV-1 and HSV-2 PCR</td>
<td>12</td>
<td>Negative</td>
</tr>
<tr>
<td>HHV-6 PCR</td>
<td>19</td>
<td>Negative</td>
</tr>
<tr>
<td>HIV RNA quantitative PCR</td>
<td>5</td>
<td>Negative</td>
</tr>
<tr>
<td>HSV DNA quantitative PCR</td>
<td>9</td>
<td>Negative</td>
</tr>
<tr>
<td>Leptospira DNA</td>
<td>14</td>
<td>Negative</td>
</tr>
<tr>
<td>Parvovirus B19 DNA</td>
<td>19</td>
<td>Negative</td>
</tr>
<tr>
<td>VZV DNA, qualitative PCR</td>
<td>19</td>
<td>Negative</td>
</tr>
<tr>
<td>Cryptococcal antigen</td>
<td>5</td>
<td>Negative</td>
</tr>
<tr>
<td>CSF studies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HSV 1 and 2 PCR</td>
<td>3</td>
<td>Negative</td>
</tr>
<tr>
<td>Fungal culture</td>
<td>3</td>
<td>Negative</td>
</tr>
<tr>
<td>Bacterial culture</td>
<td>3</td>
<td>Negative</td>
</tr>
<tr>
<td>Coccidioides Ab CF, ID</td>
<td>8</td>
<td>Negative</td>
</tr>
<tr>
<td>CMV PCR</td>
<td>9</td>
<td>Negative</td>
</tr>
<tr>
<td>EBV PCR</td>
<td>3, 9</td>
<td>Negative</td>
</tr>
<tr>
<td>HHV-6 PCR</td>
<td>3</td>
<td>Negative</td>
</tr>
<tr>
<td>JC polyomavirus DNA, PCR</td>
<td>9</td>
<td>Negative</td>
</tr>
<tr>
<td>Mycobacterial culture</td>
<td>9</td>
<td>Negative</td>
</tr>
<tr>
<td>Mycobacterium tuberculosis DNA PCR</td>
<td>10</td>
<td>Negative</td>
</tr>
<tr>
<td>Meningoencephalitis antibody panel†</td>
<td>10</td>
<td>Negative</td>
</tr>
<tr>
<td>VDRL</td>
<td>9</td>
<td>Negative</td>
</tr>
<tr>
<td>VZV Ab IgG</td>
<td>9</td>
<td>Negative</td>
</tr>
<tr>
<td>West Nile virus RNA</td>
<td>9</td>
<td>Negative</td>
</tr>
<tr>
<td>mNGS for pathogen detection</td>
<td>9</td>
<td>SLEV</td>
</tr>
<tr>
<td>Respiratory secretion testing‡</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bacterial culture</td>
<td>4, 5, 8</td>
<td>Candida albicans</td>
</tr>
<tr>
<td>Fungal culture</td>
<td>5, 8</td>
<td>C. albicans</td>
</tr>
<tr>
<td>Respiratory virus panel§</td>
<td>4 (NP swab), 5</td>
<td>Negative</td>
</tr>
<tr>
<td>Mycoplasma pneumoniae PCR</td>
<td>5</td>
<td>Negative</td>
</tr>
<tr>
<td>HSV-1 and HSV-2 PCR</td>
<td>5</td>
<td>Negative</td>
</tr>
<tr>
<td>CMV PCR</td>
<td>5</td>
<td>Negative</td>
</tr>
<tr>
<td>Pneumocystis DFA</td>
<td>5</td>
<td>Negative</td>
</tr>
<tr>
<td>Mycobacterial culture</td>
<td>5</td>
<td>Negative</td>
</tr>
<tr>
<td>Legionella culture and urinary Ag</td>
<td>5</td>
<td>Negative</td>
</tr>
<tr>
<td>Nocardia culture</td>
<td>8</td>
<td>Negative</td>
</tr>
<tr>
<td>Serologic testing</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coccidioides IgG/IgM</td>
<td>4, 9</td>
<td>Negative</td>
</tr>
<tr>
<td>Coccidioides complement fixation</td>
<td>8</td>
<td>Negative</td>
</tr>
<tr>
<td>HCV Ab</td>
<td>9</td>
<td>Negative</td>
</tr>
<tr>
<td>HBV, core Ab and hepatitis B e Ab</td>
<td>9</td>
<td>Negative</td>
</tr>
<tr>
<td>Mycobacterium tuberculosis quantiferon gold</td>
<td>8</td>
<td>Negative</td>
</tr>
<tr>
<td>Q fever antibody</td>
<td>8</td>
<td>Negative</td>
</tr>
<tr>
<td>Rapid plasma reagin</td>
<td>10</td>
<td>Negative</td>
</tr>
</tbody>
</table>

*Ab, antibody; Ag, antigen; BAL, bronchoalveolar lavage; CF, complement fixation; CMV, cytomegalovirus; DFA, direct fluorescent antigen; DNA, deoxyribonucleic acid; EBV, Epstein-Barr virus; EIA, enzyme immunoassay; HBV, hepatitis B virus; HCV, hepatitis C virus; HHV-6, human herpesvirus 6; HIV, human immunodeficiency virus, HSV, herpes simplex virus; ID, immunodiffusion; IFA, indirect fluorescent antibody; mNGS, metagenomic next-generation sequencing; NP, nasopharyngeal; RNA, ribonucleic acid; SLEV, St. Louis encephalitis virus; VRDL, Venereal Disease Research Laboratory; VZV, varicella zoster virus.

†Includes IgM and IgG testing for West Nile virus; California encephalitis virus; Eastern equine encephalitis virus; St. Louis encephalitis virus; Western equine encephalitis virus; lymphocytic choriomeningitis virus; herpes simplex virus types 1 and 2 (HSV-1 and 2); adenovirus; influenza A; influenza B; measles (IFA); mumps (IFA); varicella-zoster Ab CF; coxsackie A types 2, 4, 7, 9, 10, and 16; coxsackie B types 1, 2, 3, 4, 5, and 6; echovirus types 4, 7, 9, 11, and 30; and CMV.

‡Detects the following viruses: influenza A; influenza A H1 seasonal; influenza A H3 seasonal; influenza A 2009 H1N1; influenza B; respiratory syncytial virus A and B; paramyxoviruses 1–4; human metapneumovirus; human rhinovirus; adenovirus serogroups C and B/E; coronaviruses NL63, HKU1, 229E, and OC43.
of the predicted 10,936-bp virus genome. Subsequent mNGS testing of the patient’s CSF from hospitalization day 3 also was positive for SLEV.

The patient’s SLEV genome sequence was >99% identical with previously sequenced 2014–2015 SLEV isolates from mosquitoes in California and Arizona (4). Phylogenetic analysis placed the patient’s strain in a cluster containing these isolates and viruses sequenced from mosquitoes in Argentina in 1978 and 2005 (9) (Figure). The patient’s SLEV was genetically distinct from the 2003 Imperial Valley strain that had been circulating in California before an 11-year absence (12), suggesting that he was infected by the 2015–2016 reemergent genotype currently circulating in the southwestern United States (3,4). Furthermore, the patient’s SLEV genome was closely related to a strain sequenced from a mosquito pool collected in June 2016 from Kern County (Figure, panel A), with 99.9% pairwise nucleotide identity and only 5 single-nucleotide variants across the genome.

After extensive discussion with his wife regarding the patient’s SLEV diagnosis and poor prognosis, the patient was transitioned to comfort care on hospitalization day 23 and died the following day. Autopsy revealed residual mantle cell lymphoma and bronchopneumonia consistent with infection or chemical pneumonitis from aspiration. The diagnosis of SLEV meningoencephalitis was subsequently confirmed by positive reverse transcription PCR and virus culture testing from multiple laboratories (Table 2). However, follow-up testing for SLEV from the patient’s CSF and serum was negative.

Conclusions
We present a case of SLEV infection in an elderly immunocompromised patient hospitalized with fever and AMS.
and who experienced critical respiratory failure. Most SLEV infections are asymptomatic; when infections are symptomatic, clinical features include fever, lethargy, and confusion (1), with potential complications including sepsis, gastrointestinal hemorrhage, pulmonary embolism, and bronchopneumonia. In hindsight, SLEV infection is consistent with the patient’s clinical presentation, with pneumonia and respiratory decompensation possibly resulting from aspiration during the patient’s AMS from viral meningitis. Deaths from SLEV infection during the first 2 weeks are generally from encephalitis, whereas later deaths are more often caused by complications of hospitalization, such as this patient’s bronchopneumonia.

Routine diagnosis of SLEV is challenging because serologic testing is only performed by specialized reference laboratories, the period of viremia is brief, and molecular testing by reverse transcription PCR is not widely used. Clinicians in California might fail to consider SLEV when examining a patient with nonspecific febrile illness, especially given the lack of virus or disease activity in the state during the incubation period of the disease (4–21 days); mosquitoes are less prevalent at the higher altitudes of Payson, Arizona; and the patient’s SLEV sequence was most closely related to a strain from a June 2016 Kern County mosquito pool. Given the reemergence of SLEV in the southwestern United States, clinicians from affected areas will need to maintain a high index of suspicion for this disease, particularly during local community outbreaks or high SLEV activity detected through mosquito surveillance efforts.

**Acknowledgments**

We thank staff at the California Department of Health for their assistance in this study, including Kristina Hsieh and Artem Muradyan for validating and performing the SLEV reverse transcription PCR assay and Chris Preas and Peter Patiris for performing IgM and plaque-reduction neutralization serologic tests for SLEV and West Nile virus. We also thank the Centers for Disease Control and Prevention for confirmatory testing of the patient sample for SLEV.

The study was supported by the California Initiative to Advance Precision Medicine (C.Y.C., H.A.S., M.R.W., S.M.); an award from Abbott Laboratories, Inc. (C.Y.C.); and philanthropic grants from the Schwab Foundation (C.Y.C.) and the Sandler and William K. Bowes Foundations (C.Y.C., H.A.S., M.R.W., S.M.).

---

**Table 2. Results of follow-up confirmatory testing for SLEV after mNGS result for a patient with fatal mosquito-borne St. Louis encephalitis virus infection diagnosed by metagenomic sequencing, California, 2016**

<table>
<thead>
<tr>
<th>Test (hospital day sample collected)</th>
<th>Laboratory</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CSF studies</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SLEV, RT-PCR (9)</td>
<td>UCSF research lab</td>
<td>Positive</td>
</tr>
<tr>
<td>SLEV, RT-PCR (3,9)</td>
<td>CDPH</td>
<td>Positive</td>
</tr>
<tr>
<td>SLEV, RT-PCR (3,9)</td>
<td>CDPH</td>
<td>Positive</td>
</tr>
<tr>
<td><strong>Viral culture (3,9)</strong></td>
<td>CDCP</td>
<td>Positive, confirmed as SLEV by RT-PCR</td>
</tr>
<tr>
<td>SLEV, IgG/IgM antibody (3,9)</td>
<td>Quest Diagnostics</td>
<td>Negative, &lt;1:10</td>
</tr>
<tr>
<td>SLEV, PRNT for neutralizing antibodies (9)</td>
<td>CDPH</td>
<td>Negative, &lt;1:10</td>
</tr>
<tr>
<td><strong>WNV, IgM</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WNV, PRNT for neutralizing antibodies (9)</td>
<td>CDPH</td>
<td>Negative, &lt;1:10</td>
</tr>
<tr>
<td><strong>Serum studies</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SLEV, RT-PCR (23)</td>
<td>CDPH</td>
<td>Negative</td>
</tr>
<tr>
<td>SLEV, IgM antibody (23)</td>
<td>CDPH</td>
<td>Negative, &lt;1:10</td>
</tr>
<tr>
<td>WNV, IgM antibody (23)</td>
<td>CDPH</td>
<td>Negative, &lt;1:10</td>
</tr>
<tr>
<td>SLEV, PRNT for neutralizing antibodies (23)</td>
<td>CDPH</td>
<td>Negative, &lt;1:10</td>
</tr>
<tr>
<td>WNV, PRNT for neutralizing antibodies (23)</td>
<td>CDPH</td>
<td>Borderline positive, 1:10 (normal &lt;1:10)</td>
</tr>
</tbody>
</table>

*Tests were performed after mNGS testing of patient CSF was positive from aliquots collected on hospital days 3 and 9. CDPH, Centers for Disease Control and Prevention; CDPH, California Department of Public Health; CSF, cerebrospinal fluid; mNGS, metagenomic next-generation sequencing; PRNT, plaque-reduction neutralization testing; RT-PCR, reverse transcription PCR; SLEV, St. Louis encephalitis virus; UCSF, University of California, San Francisco; WNV, West Nile virus.
C.Y.C. is the director of the UCSF–Abbott Viral Diagnostics and Discovery Center and receives research support from Abbott Laboratories, Inc. C.Y.C., S.N.N., and S.M. are co-inventors of the sequence-based ultra-rapid pathogen identification computational pipeline (known as SURPI+) and associated algorithms; a patent pending for SURPI+ has been filed by the University of California, San Francisco.

Dr. Chiu is an associate professor at the University of California, San Francisco, who heads a translational research laboratory focused on clinical metagenomic assay development for infectious diseases and characterization of emerging outbreak viruses.

References

Address for correspondence: Charles Y. Chiu, University of California, San Francisco, Laboratory Medicine, 185 Berry St, Box 0134, UCSF China Basin, San Francisco, CA 94143-0134, USA; email: charles.chiu@ucsf.edu

Presenting a variety of infection prevention and control topics. Webinars feature CDC and external experts. Earn free continuing education credits!
Technical Appendix

Diagnostic Workup for Noninfectious Etiologies of Patient’s Illness

Prior to admission, the patient was noted to have hyperleukocytosis in an outpatient clinic with a peripheral leukocyte (leukocyte) count of 92/mm$^3$. This was attributed to his cancer treatment, and he underwent urgent leukopheresis with mild symptomatic improvement.

On hospital admission, toxicity from his chemotherapeutic regimen, in particular Ara-C, was raised as a potential etiology for the patient’s altered mental status (AMS), but was considered unlikely since he had not been administered this drug in the past 2 weeks and had not had any prior episodes of AMS in association with this drug. A transthoracic echocardiogram obtained due to dyspnea showed a mildly reduced cardiac ejection fraction of 45%–50%, and the patient was treated with diuretics. Head computed tomography scanning for an acute stroke was negative. Given his acute hypoxemia and risk of pulmonary embolism in the setting of malignancy, he was empirically started on anticoagulation, which was discontinued after a high-resolution computed tomography scan of the chest was negative.

Given a high serum ferritin level (>13,000), acute transaminitis, hypertriglyceridemia, and persistent AMS, the possibility of hemophagocytic lymphohistiocytosis (HLH) was raised. A bone marrow biopsy was performed on hospital day 11, but pathology findings were unremarkable, as were studies for heavy metal exposures (e.g., iron and copper). Although autoimmune testing by a paraneoplastic panel was negative, the patient was given 2 days of empiric intravenous immunoglobulin (IVIg) starting on hospital day 16, with mild improvement in mental status. However, the IVIg was discontinued the following day when he acutely decompensated with hypoxemia, hypertension, and flash pulmonary edema. He was treated with aggressive diuresis and antihypertensive medications and re-institution of IVIg with no
improvement. A repeat EEG was abnormal with possible seizure activity, so the patient was started on levetiracetam, with improvement in the EEG but no improvement in his mental status.

**Sample Collection and Ethics**

After obtaining informed consent from the patient’s family under protocols approved by the institutional review boards of UCLA and UCSF, the patient was enrolled in the PDAID study. CSF samples from hospital days 3 and 9 were submitted to UCSF for mNGS testing. The initially tested sample was processed from hospital days 20 to 23, and the results communicated to the providers and patient’s family on hospital day 23.

**Metagenomic Library Construction**

Separate DNA and RNA metagenomic libraries were constructed and sequenced from the patient’s CSF sample according to a standardized operating procedure (SOP) in a Clinical Laboratory Improvement Amendments (CLIA)-certified microbiology laboratory as previously described (1). For each sequencing run, the SOP includes running two external controls (1): a negative “no-template” control (NTC) sample consisting of elution buffer (2), and a positive control (PC) sample consisting of a mixture of 7 representative pathogens (CMV, HIV, *Streptococcus agalactiae, Klebsiella pneumoniae, Cryptococcus neoformans, Aspergillus niger, and Toxoplasma gondii*) spiked at concentrations 1–2 log above the estimated limits of detection. Each sample also contains two internal spiked bacteriophage controls for RNA and DNA corresponding to M2 phage and T1 phage, respectively. Metagenomic NGS data was analyzed for pathogens using SURPI+, a clinical version of the SURPI (“sequence-based ultra-rapid pathogen identification”) computational pipeline for automated detection of pathogen sequences from mNGS data (2). The March 2015 build of NCBI GenBank was used as the reference database for comparison.

Specific threshold cutoffs for organism detection were empirically chosen a priori based on data from prior extensive research-based testing of CSF samples. Briefly, the criteria for pathogen identification and reporting were as follows: (i) for reporting of bacteria, fungi, and parasites, a RPM (reads per million) ratio of $\geq 10$, defined as the $\text{RPM}_{\text{sample}} / \text{RPM}_{\text{NTC}}$ for any given taxon (species, genus, or family); (ii) for reporting of viruses, coverage at least 2 non-
contiguous / non-overlapping gene regions of size greater than the read length (140 bp). Viruses corresponding to non-pathogenic flora (e.g., anelloviruses) or contaminants found in the NTC were not reported.

**SLEV RT-PCR Confirmation**

Confirmation of SLEV detection in the research laboratory and by the California Department of Public Health and U.S. CDC was performed by virus-specific RT-PCR using primers and conditions specified in (3). The sequence of the PCR amplicon by Sanger sequencing corresponded to SLEV.

**Phylogenetic Analysis**

The genomes corresponding to the patient’s SLEV, an SLEV strain from a mosquito pool collected in 2016 from Kern County, California, and all 32 complete SLEV sequences available in NCBI GenBank as of December 2016 were aligned using the MAFFT program (4) at default settings. Phylogenetic trees were constructed using the neighbor joining algorithm with 10,000 bootstrap replicates in Geneious (5).

**GenBank Accession Numbers**

The genome sequences corresponding to the patient’s SLEV and the SLEV from a 2016 mosquito pool collected from Kern County, California have been deposited in NCBI GenBank (accession numbers KY825742-KY825743). Following removal of human sequences, metagenomic reads corresponding to the patient’s RNA and DNA libraries and control samples (NTC and PC) have been deposited in the NCBI Sequence Read Archive (SRA) (BioProject PRJNA380606, accession number SRP102510).

**References**

http://dx.doi.org/10.1101/gr.171934.113


http://dx.doi.org/10.1093/molbev/mst010

http://dx.doi.org/10.1093/bioinformatics/bts199